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Abstract 
Tumor infiltrating lymphocytes in primary breast cancer (TIL) are acknowledged 
measures of disease free survival (DFS) in adjuvant and neoadjuvant settings. Little 
is known about the biology of metastasis infiltrating lymphocytes (mTIL) although the 
local immunity of the metastatic site may critically influence the infiltrate composite. 
To address this question we compared mTIL with their matched TIL in 87 breast 
cancer patients and their corresponding distant metastasis at four different 
anatomical locations. Sections of surgical specimen were immunohistochemically 
analyzed for CD4, CD8 and CD20 positive lymphocytes in three different tumor 
compartments: intratumoral lymphocytes (iTIL) defined as lymphocytes in direct 
contact with breast cancer cells, stromal lymphocytes (sTIL) located within the 
intratumoral stromal tissue and invasive-margin lymphocytes (imTIL). Overall we 
found fewer (p < 0.001) mTIL than TIL. Within the tumor compartments imTIL were 
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more frequent than sTIL and iTIL both within metastases and the matched primary 
tumors (p < 0.001). CD4+ T cells were more numerous than CD8+ T cells and 
CD20+ B cells (p < 0.001). There was a similar pattern in primary tumors and their 
corresponding metastasis. Only patients with brain metastases differed from the 
others displaying less CD20+ B cells at the infiltrative margin of the primary tumor (p 
< 0.05). 
In summary, mTIL were significantly reduced within metastases but still mirrored the 
infiltrate pattern of the primary tumor, interestingly regardless of the metastatic 
anatomical locations investigated. Our results suggest that the primary tumor 
assigns the infiltrating lymphocyte pattern resumed at the metastatic site. 
Keywords 
tumor immunology, breast cancer, metastasis, lymphocytes 
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Abbreviations 
TIL: tumor infiltrating lymphocytes 
mTIL: infiltrating lymphocytes in metastases 
iTIL: intratumoral tumor infiltrating lymphocytes 
sTIL: stromal infiltrating intratumoral lymphocytes 
imTIL: invasive margin infiltrating intratumoral lymphocytes 
PT: primary tumor 
Met: metastatic lesion 
CTLs: cytotoxic CD8+ T cells 
Tregs: regulatory T cells 
FFPE: formalin-fixed paraffin-embedded 
DFS: disease free survival 
HE: hematoxylin and eosin 
TMA: tissue microarray 
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Introduction 
Metastatic outgrowth in distant organs is the major cause of breast cancer 
associated death. In breast cancer overt metastasis is usually detected after a 
latency period of 2-20 years after surgical removal and treatment of the primary 
tumor 1. Yet, tumor dissemination of cancer cells seems to occur even before 
primary tumors are clinically detectable 2, 3 most likely due to dormant 
micrometastatic cells referred to as microscopically undetectable metastatatic tumor 
cells presumably persisting in a growth arrest phase. 4 Among various contributing 
mechanisms the role of the immune system, particularly immunosurveillance has 
been lively discussed. 5 In this context, an important role of tumor infiltrating 
lymphocytes (TIL) was recently demonstrated in colorectal cancer. There, the 
immune contexture of TIL integrated into an immunoscore 6 was shown to 
significantly correlate with disease free survival and overall survival. Moreover, 
assessment of the immunoscore proved to be superior with regard to prognosis 
when compared to the classical TNM staging system suggesting that tumor 
progression depends on the host immune response. 7 
Generally, a more favorable prognosis is supported by a cancer-destructive 
microenvironment consisting of type I immunity such as Th1 CD4+ T cells, cytotoxic 
CD8+ T cells (CTLs) and pro-inflammatory cytokines while a type II immune 
environment limits the expansion of CTLs and promotes an immunosuppressive 
milieu dominated by regulatory T cells (Tregs) and their corresponding cytokines. 8-10 
Interestingly, the immune profile correlates with the molecular breast cancer subtype. 
In luminal breast cancers CTLs were described to be most frequent with only low 
levels of Tregs being present whereas HER2+ or basal-like subtypes showed the 
inverse immune profile. 11, 12 In line with other malignancies, depending on the TIL 
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subsets, TIL were shown to correlate with improved specific survival of breast cancer 
patients. Particularly a higher frequency of CD8+ TIL correlated with a better 
prognosis. 13, 14 TIL are associated with a better neoadjuvant chemotherapy 
response in Her2+ and triple-negative breast cancers. 15-18 
These findings have emphasized the importance of evaluating TIL and have 
supported novel immunomodulatory treatment options. Boosting T cell responses by 
anti-CTLA4 or anti-PD1 antibodies was shown to improve disease outcome in 
melanoma or lung cancer. 19-21 Immunotherapy is not yet routinely used in breast 
cancer, but was mainly applied in phase I clinical trials. 22 
In contrast to primary breast cancer infiltrating lymphocytes (TIL) little is known about 
the frequency and composition of metastasis infiltrating lymphocytes (mTIL). While 
TIL always face the local immunity of the breast mTIL are confronted with different 
on-site immunities depending on the anatomical location of metastasis. Experimental 
studies have proposed innate immunity to play a crucial role in late-stage 
carcinogenesis and metastasis outgrowth. 27-30 Yet, many of these findings are 
based on metastasis models carrying cancers selected for fast tumor and metastasis 
growth. Consequently, the human tumor biology may not be properly reflected where 
the dynamics are slower given often years until metastasis can be detected such that 
adaptive immunity may dominate even at the site of distant metastasis. 
To this end, we characterized frequencies of CD4+, CD8+ and CD20+ infiltrating 
lymphocyte subsets within three different tumor compartments using 87 primary 
breast cancer specimen and their corresponding metastatic sites in brain, bone, liver 
or soft tissue. Our results reveal a comparable distribution and composition but lower 
frequency of infiltrating lymphocyte subsets within the metastasis when compared to 
the matched primary tumor. Interestingly, we found this pattern within all metastases 
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regardless of their anatomical location suggesting that the primary tumor shapes the 
infiltrating immune cell composite rather than the metastases with their local 
immunity. 
Materials and Methods 
Patients and material cohort 
To compare the immunoprofile in primary breast cancer and their corresponding 
metastases, we searched patients with hematogeneous metastases in the archives 
of the Institute of Surgical Pathology, University Hospital Zurich in the time period of 
1995-2012. There was tissue material of 87 formalin-fixed paraffin-embedded 
(FFPE) primary breast cancer samples and their corresponding sites of distant 
metastasis available. Among the metastatic lesions, there were 46 surgical 
specimens and 41 biopsy specimens. While all primary tumor samples had been 
characterized for estrogen and progesterone receptor expression at the time of the 
primary diagnosis, samples from before 2002 had not routinely been assessed for 
their Her2 expression. Her2 Status was retrieved in all but two such cases from a 
retrospective large tissue microarray databank of the Institute of Surgical Pathology. 
Our study cohort consisted of 87 breast cancer patients suffering from either 
invasive-ductal or invasive-lobular breast cancer. Four patients were treated with a 
preoperative chemotherapy, the others underwent adjuvant treatment after surgery 
according to the time current guidelines and available regiments. Distant metastasis 
had occurred to either brain, bone, liver or soft tissue (Table 1) the most common 
sites of metastasis in breast cancer.26 In our cohort no patient suffered from more 
than one metastasis at the four investigated anatomical sites. Yet, we cannot 
exclude that patients exhibited metastases at other but the four investigated 
locations at the time of metastasis sampling such as lung metastases which may 
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have been monitored by imaging only. Approval of the use of human primary breast 
cancer samples and metastatic tissue was obtained from the official ethical 
authorities of the Canton Zurich, Switzerland (ethical approval KER-2012-553). 
Tissue blocks were cut in multiple 2 m sections for hematoxylin and eosin (HE) and 
immunohistochemical stainings. 
Immunohistochemistry 
Immunohistochemical stainings of tissue sections were performed using automated 
immunostainers (Ventana Medical Systems, Tucson, AZ, USA or Leica BOND-III, 
Leica Microsystems, Heerbrugg, Switzerland) utilizing the antibodies monoclonal 
rabbit-anti-human CD4-antibody (Ventana, clone SP35, antibody prediluted), 
monoclonal mouse-anti-human CD8-antibody (Dako, Baar, Switzerland, clone 
C8/144B, antibody dilution: 1:100) and monoclonal mouse-anti-human CD20-
antibody (Ventana, clone L26, antibody pre-diluted) with pretreatments according to 
the respective manufactures’ instructions. Antibody detections were performed with 
either Ultra View-AP Kit (substrate: New-Fuchsin) on Ventana Benchmark or Refine-
HRP-Kit on BondMax Benchmark, Leica. 
Evaluation of tumor infiltrating lymphocytes 
To accurately assess tumor infiltrating lymphocytes, we used large tissue sections. 
We evaluated the areas of interest at first on newly stained HE sections and 
determined the area based on the morphology. The immunohistochemical sections 
were corresponding to the HE areas. We distinguished three different anato-
pathological compartments on the HE sections both within the primary tumors and 
the metastatic lesions and assessed them separately, since TIL may have different 
functions and relevance towards clinical outcome or treatment response depending 
on their location. We evaluated them separately as follows: 
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iTIL: Areas within the invasive tumor cells, mainly in closely packed pattern without 
relevant intervening stroma between the invasive tumor cells. This compartment 
represents a direct contact of TIL with the tumor cells. 
sTIL: Interstitial areas within the invasive tumor area containing sufficient amount of 
connective tissue without the presence of invasive tumor cells. 
imTIL: Peripheral areas of the invasive tumor cells representing the invasion front of 
the tumor. 
The assessment of the immunohistochemical stains was conducted in all three 
anato-pathological compartments in an identical manner: three different areas of 
interest in the 40x objective magnification were evaluated in a semi-quantitative way 
following a recently recommended assessment in the literature for breast cancer 24. 
The frequency of TIL was given in a semi-quantitative scale (results in 5% steps 
beginning with 0%) as percentage of stained lymphocytes per 40x objective field in 
the specific investigated compartment area. One field of pre-defined interest may 
correspond to max. 1mm2. Importantly, TIL scoring was performed as the percentage 
only of the given predefined tumor compartment alone, areas not belonging to the 
given compartment were not included in the assessed surface area. In order to 
minimize biasing due to tumor heterogeneity we evaluated three different areas per 
respective tumor compartment of each section. The average percentages of these 
three fields per TIL subset and per tumor compartment were used for further 
evaluation such as calculation of mean and median. Illustrative areas of all three 
compartments in primary and metastatic lesions are shown in a representative 
primary breast cancer with its corresponding brain metastasis (Fig. 1). 
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Scores were assessed in the first run by two pathologists (ZV, BS) and were 
randomly re-assessed by one investigator (BS) after a period of time of at least a few 
weeks. 
Statistical analysis 
Evaluation of the TIL frequencies and their correlation to clinicopathological 
parameters was performed using one-way ANOVA analysis with Bonferroni post 
testing. Disease free survival defined as the time between diagnosis of the primary 
tumor and the occurrence of the respective distant metastasis was computed using 
Kaplan-Meier estimator. All data are shown as mean with standard deviation (SD). 
Significances are displayed as follows: ns = p > 0.05, * = p ≤ 0.05, ** = p ≤ 0.01, *** = 
p ≤ 0.001 and **** = p ≤ 0.0001. Analyses were performed using SPSS (version 22) 
and GraphPad Prism (version 5.04) software. 
Results 
We semi-quantitatively analyzed CD4+, CD8+ and CD20+ infiltrating lymphocyte 
(TIL) subsets within three tumor compartments. According to previous 
recommendations in literature (24 also see Material and Methods), we evaluated 
intratumoral (iTIL) and stromal (sTIL) percentage of TIL for the primary tumor (PT) 
and the site of metastasis (Met) in each case as well as TIL at the invasive margin 
(imTIL) for each primary tumor and also for some metastatic lesions with clear 
infiltrative margins. Due to rather diagnostic biopsy sampling than total resection of 
distant metastasis the invasive margin was available in only 48 % of all 
corresponding metastases. 
Distribution of TIL in primary tumor 
Within the primary tumors we found significantly more imTIL than sTIL and iTIL than 
in the metastases (p<0.0001) (Tables 2, 3). This finding was irrespective of the 
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anatomical site of their metastasis (Fig. 2 A-D). Lymphocyte subsets consistently 
displayed a distribution pattern with CD4+ TIL being most frequent followed by CD8+ 
TIL and finally CD20+ TIL within the stromal and invasive margin compartment again 
irrespectively of the site of metastasis (Fig. 2 A-D). This TIL distribution pattern was 
not as evident for the intratumoral compartment (Table 2) generally displaying very 
low frequencies of TIL. As such, for all primary tumors the average CD4/CD8 ratio 
for sTIL and imTIL was >1. Additionally, in all three tumor compartments CD20+ TIL 
were generally less frequent than infiltrating T cells. 
Distribution of TIL in the metastastic lesions 
With respect to the corresponding sites of metastasis, in general mTIL were less 
frequent in the metastatic lesions than TIL of the primary tumor (Tables 2 and 3). 
The distribution pattern of mTIL within the compartments displayed a similar 
tendency both for the frequency (sTIL>iTIL) and for the composition of the TIL 
subsets (frequency of CD4+TIL>CD8+TIL>CD20+TIL) irrespectively of the 
anatomical site at which metastasis had occurred (Table 3). When comparing the 
frequency of TIL subsets within the two investigated compartments we found 
significantly more CD4+ and CD8+ TIL in the primary tumor than in the metastases 
(Fig. 3 A-D, showing stromal compartiments). 
Different distribution pattern of TIL in primary and metastastic lesions 
We observed a distinct TIL distribution pattern schematically summarized as 
imTIL>sTIL>iTIL (Fig. 3 E) and CD4+TIL>CD8+TIL>CD20+TIL subsets (Fig. 3 F). 
We found this distribution pattern within the primary tumor and the site of the 
corresponding metastasis, irrespectively of the anatomical site at which metastasis 
had occurred. 
Correlation of TIL in primary and metastastic lesions with disease free survival 
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High numbers of CD8+ TIL at the invasive margin were associated with a longer 
DFS (p<0.05) whereas low numbers of CD8+ imTIL correlated with a shorter DFS 
regarding the whole cohort. Interestingly, if the results were stratified according to 
the site of the metastatic lesion, we could not determine any correlation to DFS and 
imCD8 + T cells among cases with soft tissue metastases, however, patients with 
metastasis to brain, bone or liver exhibited the same survival benefit of increased 
imCD8+ T cells (Fig. 4). In contrast, there was no significant correlation to DFS with 
regard to the frequency of CD4 positive TIL in any locations analyzed (data not 
shown). 
Correlation of intrinsic subtypes and metastatic sites to overall survival and 
ITL in patients with brain metastases 
Patients with brain metastasis differed from the other breast cancer patients suffering 
from bone, liver or soft tissue metastasis in terms of clinic-pathological data and 
CD20+ imTIL. Patients developing brain metastasis were significantly younger at the 
age of the onset of the primary tumor and the metastasis (Fig. 5 A). They had a 
significantly shorter disease free survival (Fig. 5 B) and displayed most often HER2+ 
or basal like breast cancer subtypes. (Fig. 5 C). Interestingly, we found significantly 
less CD20+ imTIL in those primary tumors metastasizing into the brain when 
compared to the primary tumor groups showing bone, liver or soft tissue metastasis 
(Fig. 5 E). Additionally, Luminal A and Luminal B tumors displayed a similar long 
term better overall survival than HER2 positive and TN cases, which showed also a 
similar follow-up (Fig. 5 F). There was no correlation between TIL with any of the 
analyzed markers and the anatomical compartments and the intrinsic subtypes when 
analyzed separately. 
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Discussion 
We investigated TIL at four different anatomical sites at which metastasis had 
occurred and compared amount and frequency of TIL with their matched TIL in the 
primary breast cancer. In our study we could demonstrate that TIL were significantly 
reduced in the corresponding metastastic site if compared with the primary tumor. 
However, the composition of the TIL subsets and their distribution in the predefined 
anato-pathological locations remained basically unaltered in the metastatic process 
irrespectively from the anatomical site of the metastases. As to the prognostic value 
of TIL, we could show that patients with brain metastases exhibited a different 
clinical course including younger age at the time of metastases and a distinct 
immunophenotype regarding CD20 positive B-cells at the infiltration margin. 
We subdivided infiltrating lymphocytes into intratumoral, stromal and infiltrative 
margin TIL, corresponding to the three established tumor compartments debated to 
fulfill functionally different roles. 24 For this purpose we considered large sections 
superior to punched material applied for the widely-used tissue microarray (TMA) 
investigations. Important features such as the invasive margin compartment may 
potentially be underrepresented both due to the method itself and due to tumor and 
lymphocyte inhomogeneity. 
By applying the recently suggested method by Salgado et al. 24, in evaluating TIL 
overall we found fewer mTIL than their corresponding TIL irrespective of the site of 
metastasis. This was in line with results described in a small cohort pilot study using 
TMA material from primary and matched metastatic breast cancer. 31 With regard to 
the three tumor compartments we observed an TIL gradient with TIL being most 
present at the invasive margin followed by stromal TIL and least frequent within the 
tumor center. As recently reviewed in detail 24 iTIL were detected in lower numbers 
D
ow
nl
oa
de
d 
by
 [U
ZH
 H
au
ptb
ibl
iot
he
k /
 Z
en
tra
lbi
bli
oth
ek
 Z
ür
ich
], 
[Z
su
zs
an
a V
arg
a] 
at 
07
:11
 10
 M
ay
 20
16
 
 13 
 
than sTIL or imTIL. Interestingly, we observed this trend also in the metastases 
independently of the anatomical site at which metastasis had occurred. Regarding 
the TIL subtypes we found higher infiltrates of CD4+ TIL than CD8+ TIL 
corresponding to a CD4/CD8 ratio > 1. We observed higher infiltrates of CD8+ TIL to 
correlate with a better disease free survival in line with previous studies describing 
CD8+ TIL to be associated with a better clinical outcome and prognosis in breast 
cancer. 13, 14, 32 However, patients with soft tissue metastases, could not be further 
stratified based on their CD8 positive T cells. Interestingly, TIL in the metastastic 
lesions displayed a similar arrangement of lymphocyte subsets with CD4+ T cells 
being most abundant followed by CD8+ T cells and CD20+ B cells. It is therefore to 
assume, that the composition of mTIL in the metastastic site mirrors TIL in their 
matched primary tumor regardless of the anatomical metastatic location suggesting 
an intrinsic role of the primary tumor influencing the immune composition at least for 
the metastatic sites investigated. 
Apart from these findings, patients suffering from brain metastasis differed from the 
other patients both with respect to their clinicopathological parameters and their TIL 
distribution. In line with previous findings their primary tumors displayed significantly 
more HER2+ or basal like subtypes (p < 0.01), patients were younger at the time of 
diagnosis (p < 0.05) and suffered from a shorter distant metastasis-free survival (p < 
0.01).38 Curiously, we found less (p < 0.05) CD20+ imTIL in primary tumors 
metastasizing into the brain. While some groups describe a metastasis-promoting 
behavior of CD20+ TIL others suggested B cells to contribute to anti-tumor immunity 
by antibody production.39-41 According to the latter, in our case the significantly 
reduced number of CD20+ imTIL may have added to the aggressive behavior of 
these primary tumors preferably metastasizing to the brain. 
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In conclusion, our data propose an intrinsic role of the primary tumor influencing the 
immune composition within the corresponding metastasis at least for the metastatic 
sites investigated. Further investigation is required to find out whether an individual 
“tumor immune signature” could already be established by characterizing the TIL 
composite within the primary tumor potentially allowing a targeted treatment of the 
corresponding metastatic disease. 
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Table 1. Clinicopathological data of the 87 breast cancer patients investigated. 
Clinicopathological data and group distribution of the 87 breast cancer patients with 
respect to the four anatomical locations at which the corresponding metastasis had 
occurred. Percentages are shown in relation to the respective metastatic site. 
Clinicopathological 
Parameters  
Site of Metastasis 
Brain (n=21) Bone (n=24) Liver (n=11) Soft tissue 
(n=31) 
No. % No. % No. % No. % 
 Age at initial 
diagnosis 
        
Age < 55 15 71.4% 9 37.5% 4 36.4% 12 38.7% 
Age ≥ 55 6 28.6% 15 62.5% 7 63.6% 19 61.3% 
Histological 
Subtype 
        
invasive-ductal 20 95.2% 18 75.0% 11 100.0% 25 80.6% 
invasive-lobular 1 4.8% 6 25.0% 0 0.0% 6 19.4% 
Tumor (T) stage         
T1 6 28.6% 6 25.0% 4 36.4% 8 25.8% 
T2 10 47.6% 16 66.7% 6 54.5% 20 64.5% 
T3 4 19.0% 1 4.2% 1 9.1% 2 6.5% 
T4 1 4.8% 1 4.2% 0 0.0% 1 3.2% 
Nodal (N) stage         
Negative 5 23.8% 11 45.8% 2 18.2% 12 38.7% 
Positive 16 76.2% 13 54.2% 9 81.8% 19 61.3% 
Tumor grade         
Grade 1 0 0.0% 1 4.2% 1 9.1% 3 9.7% 
Grade 2 3 14.3% 12 50.0% 2 18.2% 17 54.8% 
Grade 3 18 85.7% 11 45.8% 8 72.7% 11 35.5% 
ER status         
Negative 16 76.2% 2 8.3% 2 18.2% 7 22.6% 
Positive 5 23.8% 22 91.7% 9 81.8% 24 77.4% 
PR status         
Negative 18 85.7% 7 29.2% 6 54.5% 19 61.3% 
Positive 3 14.3% 17 70.8% 5 45.5% 12 38.7% 
Her2 status         
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negative 8 38.1% 21 87.5% 8 72.8% 27 87.1% 
positive 13 61.9% 2 8.4% 3 27.2% 3 9.7% 
Unknown 0 0 1 4.1% 0 0 1 3.2% 
 
  
D
ow
nl
oa
de
d 
by
 [U
ZH
 H
au
ptb
ibl
iot
he
k /
 Z
en
tra
lbi
bli
oth
ek
 Z
ür
ich
], 
[Z
su
zs
an
a V
arg
a] 
at 
07
:11
 10
 M
ay
 20
16
 
 25 
 
Table 2. Distribution of tumor infiltrating lymphocytes (TIL) subsets within the primary 
tumor. Mean and median are displayed for CD4+, CD8+ and CD20+ lymphocytes 
within the three investigated primary tumor compartments consisting of intratumoral 
(iTIL), stromal (sTIL) and invasive margin (imTIL) TIL divided into the four anatomical 
sites (brain, bone, liver and soft tissue) of the corresponding metastasis. 
TIL within the 
primary tumor 
Site of Metastasis 
Brain (n=21) Bone (n=24) Liver (n=11) Soft tissue 
(n=31) 
Mean Median Mean Median Mean Median Mean Median 
iCD4+ T cells 4.8 3.7 5.1 2.3 1.8 .7 7.3 5.3 
iCD8+ T cells 5.7 3.7 12.7 8.3 4.8 2.0 9.3 6.7 
iCD20+ B cells .7 .3 .3 .3 .4 .3 .5 .3 
sCD4+ T cells 18.0 13.3 19.4 16.7 11.6 13.3 21.3 20.0 
sCD8+ T cells 11.4 8.3 14.8 12.5 7.1 6.7 16.2 13.3 
sCD20+ B cells 1.2 .3 2.0 .7 2.0 .7 4.5 2.0 
imCD4+ T cells 42.9 36.7 38.8 33.3 38.8 26.7 39.2 36.7 
imCD8+ T cells 26.6 20.0 28.0 23.3 22.3 13.3 31.1 26.7 
imCD20+ B cells 5.6 5.0 11.1 7.5 10.1 8.3 20.6 16.7 
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Table 3. Distribution of metastasis infiltrating lymphocytes (mTIL) subsets within the 
site of metastasis. Mean and median are displayed for CD4+, CD8+ and CD20+ 
lymphocytes within the two investigated metastasis compartments consisting of 
intratumoral (iTIL) and stromal (sTIL) divided into the four anatomical sites (brain, 
bone, liver and soft tissue) of the corresponding metastasis. 
TIL within the site 
of metastasis 
Site of Metastasis 
Brain (n=21) Bone (n=24) Liver (n=11) Soft tissue 
(n=31) 
Mean Median Mean Median Mean Median Mean Median 
iCD4+ T cells 2.3 2.0 1.2 .3 .8 .3 7.3 5.0 
iCD8+ T cells 3.1 2.0 2.8 .7 1.1 .7 4.9 3.7 
iCD20+ B cells .4 .3 .3 .3 .3 .3 1.2 .3 
sCD4+ T cells 7.9 7.0 4.9 2.2 2.6 .7 15.1 8.3 
sCD8+ T cells 6.2 6.7 3.2 2.2 4.4 5.0 10.5 8.3 
sCD20+ B cells 1.8 .3 .6 .3 .5 .3 5.2 2.0 
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Figure 1. Distribution pattern of TIL subsets in the three tumor 
compartment of a representative primary breast cancer and its 
corresponding brain metastasis. Illustration of a primary breast 
carcinoma and its corresponding brain metastasis with HE as well as 
CD4, CD8 and CD20 immunostainings in all three examined tumor 
compartments are depicted (iTIL: intratumoral infiltrating lymphocytes, 
sTIL: stromal infiltrating lymphocytes, imTIL: infiltrative margin infiltrating 
lymphocytes). 
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Figure 2. Similar distribution of TIL with regard to the investigated 
primary tumor compartments and the lymphocyte subtypes but 
irrespectively of the site of distant metastasis. Scatter graphs show that 
within the primary tumor compartments (iTIL (not shown), sTIL and 
imTIL) invasive margin (imTIL) are significantly increased when 
compared to stromal (sTIL) TIL irrespectively of the particular site (A-D) 
to which metastasis had occurred. For all three compartments (iTIL not 
shown) CD4+, CD8+ and CD20+ lymphocyte subsets always followed 
the same gradient with CD4+ lymphocytes being the most prominent, 
followed by CD8+ lymphocytes and at last CD20 + lymphocytes again 
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irrespectively of the anatomical site of distant metastasis (A-D). 
Significances are displayed as follows: ns = p > 0.05, * = p ≤ 0.05, ** = p 
≤ 0.01 , *** = p ≤ 0.001 and **** = p ≤ 0.0001. 
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Figure 3. Significantly more sTIL within the primary tumor than mTIL within the site of 
the corresponding metastasis. Bar graphs for CD4+, CD8+ and CD20+ 
stromal infiltrating lymphocyte subsets show that there are significantly 
more sTIL within the primary tumor than mTIL within the site of the 
corresponding metastasis irrespectively of the anatomical site of distant 
metastasis (A-D). The distribution of infiltrating lymphocytes is 
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schematically visualized with respect to the three primary 
tumor/metastasis compartments (E) consisting of intratumoral 
lymphocytes (iTIL_PT/iTIL_Met = white dots), stromal lymphocytes 
(sTIL_PT/sTIL_Met = grey dots) and invasive margin lymphocytes 
(imTIL_PT/imTIL_Met = black dots) and with respect to the lymphocyte 
subsets within these compartments (F) comprising CD4+ infiltrating 
lymphocytes (red dots), CD8+ infiltrating lymphocytes (green dots) and 
CD20+ infiltrating lymphocytes (blue dots). Significances are displayed 
as follows: ns = p > 0.05, * = p ≤ 0.05, ** = p ≤ 0.01 , *** = p ≤ 0.001 and 
**** = p ≤ 0.0001. 
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Figure 4. Higher amounts of CD8+ lymphocytes within the invasive 
margin is associated with significantly longer disease free survival 
(DFS). Kaplan-Meier plots of disease free survival dichotomized at the 
respective CD8+ imTIL median of the primary tumor (also see Table 2) 
into CD8+ T cells high and CD8+ T cells low show that higher amounts 
of CD8+ T cells within the invasive margin of the primary tumor are 
generally (A) but also in the subgroups with distant metastasis into brain 
and bone except for soft tissue metastasis associated with a with 
significantly longer DFS again (B-D). 
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Figure 5. Clinico-pathological correlation of intrinsic subtypes and 
different metastastic sites of breast cancer to overall survival and to 
CD20 distribution at the invasion front. Brain metastasis group shows 
different clinicopathological and CD20+ imTIL behavior. Patients with 
distant metastasis to the brain show a significantly younger age at onset 
of both primary tumor and metastasis when compared to the other 
groups (A). Time to occurrence of distant brain metastasis (= disease 
free survival) is significantly reduced in the brain group when compared 
to all other groups (B). Patients with brain metastasis show significantly 
less estrogen receptor (ER) and progesterone (PR) but significantly 
more Her2 receptor expression in the primary tumor (C,D). Curiously, 
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CD20 tumor infiltrating lymphocytes at the infiltrative margin (imTIL) of 
the primary tumor are significantly reduced in the brain group when 
compared to the other groups where distant metastasis had occurred to 
bone, liver or soft tissue (E). When correlating intrinsic subtypes to 
overall survival, Luminal A and Luminal B tumors are separated from 
HER2 positive and TN breast cancer cases by a similarly improved 
overall survival (F). 
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